Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Molecular Cancer Research : MCR|May 5, 2021
Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the BreastJoseph L Sottnik, Evelyn K Bordeaux, Sanjana Mehrotra, et al.
Cancer Research|March 10, 2021
Androgen Receptor Regulates CD44 Expression in Bladder CancerJoseph L Sottnik, Lauren Vanderlinden, Molishree Joshi, et al.
Cancers|October 15, 2020
Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4Madeleine T Shackleford, Deviyani M Rao, Evelyn K Bordeaux, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
<i>CDH1</i> loss remodels gene expression and lineage identity in human mammary epithelial cellsMaggie Musick, Chinasa A Ufondu, Carmen E Rowland, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Metastatic cells are preferentially vulnerable to lysosomal inhibitionMichael J Morgan, Brent E Fitzwalter, Charles R Owens, et al.
The Journal of Biological Chemistry|November 20, 2019
Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine <i>O-</i>acyltransferase or Wnt secretionDeviyani M Rao, Madeleine T Shackleford, Evelyn K Bordeaux, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodelingJoseph L Sottnik, Mary E Buchanan, Maria J Contreras-Zárate, et al.
Carcinogenesis|November 8, 2018
Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered miceJoseph L Sottnik, Vandana Mallaredy, Ana Chauca-Diaz, et al.
Cancer Research Communications|December 19, 2023
WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic CancersJoseph L Sottnik, Madeleine T Shackleford, Sydney K Robinson, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Pageof 3